LncRNA BDNF-AS is associated with the malignant status and regulates cell proliferation and apoptosis in osteosarcoma.

Qiang Huang,Jiao Yang,Xin He,Shuxing Xing,Shuyan Shi

doi:10.1042/bsr20181498

Abstract

Long non-coding RNA (LncRNA) brain-derived neurotrophic factor antisense (BDNF-AS) has been found to be down-regulated and function in a tumor suppressive role in human cancers. However, the expression status and function of BDNF-AS is still unknown in osteosarcoma (OS). In our study, BDNF-AS expression was found to be decreased in OS tissues and cells. Moreover, BDNF-AS low expression was correlated with advanced Enneking stage, large tumor size and poor prognosis in OS patients. The multivariate analysis suggested low expression of BDNF-AS was an independent unfavorable prognostic factor for overall survival in OS patients. The in vitro studies indicated that BDNF-AS overexpression inhibits OS cell proliferation and promotes cell apoptosis through regulating cleaved caspase-3. In conclusion, BDNF-AS serves as a tumor suppressive lncRNA in OS.

Highlights

Osteosarcoma (OS) is the most common malignant bone tumor, and the major causes of cancer–associated mortality in children and young adults [1]
To determine the expression status of brain-derived neurotrophic factor antisense (BDNF-AS) in OS tissue, the levels of BDNF-AS expression were detected in 35 pairs of OS tissues and non-cancerous normal tissues through quantitative real-time PCR
Compared with non-cancerous normal tissues, low expression of BDNF-AS was observed in OS tissues (P

Summary

Introduction

Osteosarcoma (OS) is the most common malignant bone tumor, and the major causes of cancer–associated mortality in children and young adults [1]. An updated cancer statistics suggested that 24000 new OS cases occurred and 17000 cases died from OS in China in 2014 [2]. OS is derived from primitive mesenchymal stem cells characterized by high malignancy, frequent recurrence, and distant metastasis [3]. The 5-year survival rate of advanced OS patients is only 27.4% [5]. It is necessary for improving the prognosis of OS patients to illuminate the pathogenesis and progression of OS and identify novel biomarkers

Methods

Results

Conclusion